Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) appointed Dr. Jeffrey Jonas to its Board of Directors effective immediately and announced the retirement of Thomas Lönngren at the end of December after more than six years of service.
Dr. Jonas brings more than 30 years of pharmaceutical R&D and neuroscience leadership, executive experience at Sage Therapeutics and Shire, current board roles at Generation Bio (GBIO) and Noema Pharma, and an extensive publication record; the company cited his expertise as supportive for potential commercialization of COMP360.
Compass Pathways (Nasdaq: CMPS) will report its third quarter financial results for the period ended September 30, 2025 on November 4, 2025. Management will provide an update on recent developments and host a conference call on November 4, 2025 at 8:00 AM ET (1:00 PM UK). A live webcast will be available at the company events page and will be archived for 30 days.
Investors can access the webcast at: https://events.q4inc.com/attendee/698442687.
Compass Pathways (NASDAQ:CMPS) has published results from its Phase 2 study of COMP360 psilocybin for Post-Traumatic Stress Disorder (PTSD) in the Journal of Psychopharmacology. The study evaluated a single 25mg dose in 22 patients across sites in the U.S. and U.K.
Key findings demonstrate that COMP360 was well-tolerated with no serious adverse events. The treatment showed significant efficacy with 81.8% response rate at week 4 and 77.3% at week 12. Patients experienced substantial symptom improvement, with a 29.9-point reduction in CAPS-5 scores at week 4 and 29.5-point reduction at week 12. Notably, remission rates were 63.6% at week 4 and 54.5% at week 12.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in four major investor conferences in September 2025. The company will engage in fireside chat sessions at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit.
All sessions will be available via live audio webcast through the company's investor relations website, with replays accessible for 30 days after each event.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management will deliver a presentation on August 12, 2025, at 4:00 PM ET in Boston, MA.
Investors can access the presentation through the "Events" page in the Investors section of Compass's website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ:CMPS) reported Q2 2025 financial results and significant clinical progress. The company achieved a positive primary endpoint in its first COMP360 Phase 3 trial for Treatment-Resistant Depression (TRD), demonstrating clinically meaningful depression reduction at 6 weeks with high statistical significance. The second Phase 3 trial continues enrollment with 26-week data expected in H2 2026.
Financial highlights include a cash position of $221.9 million as of June 30, 2025, providing runway into 2027. Q2 2025 net loss was $38.4 million ($0.41 per share). The company expects FY2025 net cash used in operating activities between $120-145 million.
Research and development expenses increased to $30.3 million in Q2 2025, primarily due to advancing Phase 3 trials. The company is exploring options for potential accelerated COMP360 filing for TRD following positive trial results.
Compass Pathways (NASDAQ: CMPS), a mental health biotech company, has appointed Justin Gover to its Board of Directors. Gover brings over 25 years of biopharmaceutical leadership experience, notably as founding CEO of GW Pharmaceuticals, which he led to a $7 billion acquisition by Jazz Pharmaceuticals in 2021.
The appointment comes at a crucial time as Compass advances toward potential regulatory approval following successful Phase 3 trial results for COMP360 in treatment-resistant depression (TRD). Dr. Linda McGoldrick will retire from the Board in October 2023 after serving for over 5 years, including through the company's 2020 IPO.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has scheduled its second quarter 2025 financial results announcement for July 31, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) to discuss the financial results and provide updates on recent developments.
A live webcast will be available on the company's website and will remain archived for 30 days following the presentation.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the HC Wainwright @Home Series. The company's management will engage in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright, scheduled for July 14th, 2025, at 8:00 AM ET.
Investors can access the live audio webcast through the "Events" page in the Investors section of Compass's website. The recording will remain available for 30 days after the event.